Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

Bristol-Myers Squibb Company and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.

10 Nov 2009

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.

10 Nov 2009

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

OriGene Technologies, Inc. today announced Royal Institute of Technology in Sweden has adopted its VERIFY Tagged Antigen(TM) (Over-expression Lysates) in the Human Protein Atlas program. This program is funded by the Knut and Alice Wallenberg Foundation and is set up to explore the human proteome systematically using Antibody-Based Proteomics.

10 Nov 2009

Exposure to common infections may increase stroke risk

Cumulative exposure to five common infection-causing pathogens may be associated with an increased risk of stroke, according to a report posted online today that will appear in the January 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

10 Nov 2009

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine.

10 Nov 2009

New multi-array technology package to diagnose complex food allergies

Today at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology, Phadia US introduced two new products designed specifically to meet the unique needs of the nation’s 6,000 allergists.

10 Nov 2009

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.

10 Nov 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

An analysis demonstrating the ability of DX-88 (ecallantide) to resolve symptoms of acute hereditary angioedema (HAE) attacks in all anatomic locations and to sustain effect will be presented in an oral presentation this week at the American College of Allergy, Asthma and Immunology (ACAAI) 2009 Annual Meeting in Miami Beach.

9 Nov 2009

Rituximab drug potentially effective for treating Graves' eye disease, shows study

A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.

7 Nov 2009

GTC Biotherapeutics announces financial results for third quarter 2009

GTC Biotherapeutics, Inc.’s total net loss for the third quarter ended September 27, 2009 was $5.1 million, or $0.48 per share, compared with $6.1 million, or $0.59 per share, in the third quarter of 2008. The total net loss for the first nine months of 2009 was $26.2 million, or $2.51 per share, compared to $16.5 million, or $1.71 per share, for the first nine months of 2008.

6 Nov 2009

National Institutes of Health grants $6-million for brain disease research

Brown University, in collaboration with two other institutions, has been awarded a five-year, $6-million National Institutes of Health program project grant to help determine how a virus that can cause a rare brain disease attaches to host cells.

6 Nov 2009

New findings may lead to novel therapeutic approaches for HIV and prostate cancer

New Haven, Conn.-Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.

6 Nov 2009

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.

6 Nov 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

A new study provides evidence that ImmunoLin®, an all natural and GRAS approved source of immunoglobulin, will provide immediate benefit to the function of the immune system and the gut. Immunoglobulins, or antibodies, are specialized proteins found in blood that the immune system naturally produces for immunity.

6 Nov 2009

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

In diseases such as multiple sclerosis, cells of the immune system infiltrate the brain tissue, where they cause immense damage. For many years, it was an enigma as to how these cells can escape from the bloodstream. This is no trivial feat, given that specialized blood vessels act as a barrier between the nervous system and the bloodstream.

6 Nov 2009

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

5 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

Dietary options and better detection improve food allergy management procedures

Less restrictive dietary options, better detection, targeted avoidance measures, educational directives and potential new therapies are improving food allergy management and giving hope to the more than 12 million Americans affected according to experts at the thirteenth international food allergy conference held during the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

5 Nov 2009

Antibody News and Research

Further Reading

Bristol-Myers Squibb and Alder Biopharmaceuticals collaborate in development of novel biologic for rheumatoid arthritis

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

OriGene Technologies' over-expression lysates adopted for Human Protein Atlas project

Exposure to common infections may increase stroke risk

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

New multi-array technology package to diagnose complex food allergies

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

Rituximab drug potentially effective for treating Graves' eye disease, shows study

GTC Biotherapeutics announces financial results for third quarter 2009

National Institutes of Health grants $6-million for brain disease research

New findings may lead to novel therapeutic approaches for HIV and prostate cancer

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

ImmunoLin provides immediate benefit to the function of immune system and gut

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

New biosensor device may help in combating cancer

Dietary options and better detection improve food allergy management procedures

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News